| Literature DB >> 32718024 |
Lavinia Fabeni1, Maria Mercedes Santoro2, Patrizia Lorenzini3, Stefano Rusconi4, Nicola Gianotti5, Andrea Costantini6, Loredana Sarmati7, Andrea Antinori3, Francesca Ceccherini-Silberstein2, Antonella d'Arminio Monforte8, Annalisa Saracino9, Enrico Girardi10.
Abstract
We aimed at evaluating the characteristics of HIV-1 molecular transmission clusters (MTCs) among natives and migrants living in Italy, diagnosed between 1998 and 2018. Phylogenetic analyses were performed on HIV-1 polymerase (pol) sequences to characterise subtypes and identify MTCs, divided into small (SMTCs, 2-3 sequences), medium (MMTCs, 4-9 sequences) and large (LMTCs, ≥10 sequences). Among 3499 drug-naïve individuals enrolled in the Italian Cohort Naive Antiretroviral (ICONA) cohort (2804 natives; 695 migrants), 726 (20.8%; 644 natives, 82 migrants) were involved in 228 MTCs (6 LMTCs, 36 MMTCs, 186 SMTCs). Migrants contributed 14.4% to SMTCs, 7.6% to MMTCs and 7.1% to LMTCs, respectively. HIV-1 non-B subtypes were found in 51 MTCs; noteworthy was that non-B infections involved in MTCs were more commonly found in natives (n = 47) than in migrants (n = 4). Factors such as Italian origin, being men who have sex with men (MSM), younger age, more recent diagnosis and a higher CD4 count were significantly associated with MTCs. Our findings show that HIV-1 clustering transmission among newly diagnosed individuals living in Italy is prevalently driven by natives, mainly MSM, with a more recent diagnosis and frequently infected with HIV-1 non-B subtypes. These results can contribute to monitoring of the HIV epidemic and guiding the public health response to prevent new HIV infections.Entities:
Keywords: bioinformatics; cluster detection; drug resistance testing; human immunodeficiency virus (HIV); migrants; molecular epidemiology; phylogenetic analysis; risk factors; subtypes; transmission networks and clusters
Year: 2020 PMID: 32718024 PMCID: PMC7472346 DOI: 10.3390/v12080791
Source DB: PubMed Journal: Viruses ISSN: 1999-4915 Impact factor: 5.048
Patient’s characteristics and factors associated with HIV-1 molecular transmission clusters.
| Variables | Overall | Out of Cluster | In Cluster | Adjusted Model b | |||
|---|---|---|---|---|---|---|---|
| 2773 (79.3%) | 726 (20.7%) | OR | (95% CI) | ||||
|
| 2872 (82.1%) | 2187 (78.9%) | 685 (94.3%) | <0.001 | - | - | - |
|
| 37 (30–45) | 38 (31–46) | 32 (27–40) | <0.001 | 0.65 | 0.59–0.72 | <0.001 |
|
| |||||||
| F heterosexual | 553 (15.8%) | 513 (18.5%) | 40 (5.5%) | <0.001 | 1.00 | - | - |
| F IVDU | 32 (0.9%) | 31 (1.1%) | 1 (0.1%) | 0.49 | 0.06–3.80 | 0.497 | |
| M heterosexual | 713 (20.4%) | 628 (22.7%) | 85 (11.7%) | 1.82 | 1.19–2.78 | 0.006 | |
| M IVDU | 161 (4.6%) | 145 (5.2%) | 16 (2.2%) | 1.52 | 0.80–2.90 | 0.204 | |
| MSM | 1789 (51.1%) | 1247 (45.0%) | 550 (75.8%) | 3.46 | 2.39–5.03 | <0.001 | |
| Other/unknown | 251 (7.2%) | 209 (7.5%) | 34 (4.7%) | 2.73 | 1.66–4.48 | <0.001 | |
|
| |||||||
| Italy | 2804 (80.1%) | 2160 (77.8%) | 644 (88.7%) | <0.001 | 1.00 | - | - |
| Africa | 219 (6.3%) | 212 (7.7%) | 7 (0.9%) | 0.18 | 0.08–0.39 | <0.001 | |
| Central and South America | 241 (6.9%) | 201 (7.3%) | 40 (5.5%) | 0.49 | 0.33–0.71 | 0.001 | |
| Europe | 187 (5.3%) | 159 (5.7%) | 28 (3.9%) | 0.29 | 0.08–0.97 | 0.045 | |
| Asia | 38 (1.1%) | 35 (1.3%) | 3 (0.4%) | 0.62 | 0.40–0.97 | 0.035 | |
| Other | 10 (0.3%) | 6 (0.2%) | 4 (0.6%) | 2.61 | 0.62–10.97 | 0.189 | |
|
| |||||||
| Primary school | 169 (4.8%) | 158 (5.7%) | 11 (1.5%) | <0.001 | 0.87 | 0.45–1.71 | 0.691 |
| Secondary school | 585 (16.7%) | 505 (18.2%) | 80 (11.0%) | 0.91 | 0.68–1.21 | 0.518 | |
| College/University | 1762 (50.4%) | 1329 (47.9%) | 433 (59.6%) | 1.00 | - | ||
| Unknown | 983 (28.1%) | 781 (28.2%) | 202 (27.8%) | 1.03 | 0.83–1.28 | 0.773 | |
|
| |||||||
| Employed | 1476 (42.2%) | 1148 (41.4%) | 328 (45.2%) | <0.001 | 1.00 | - | - |
| Unemployed | 461 (13.2%) | 389 (14.0%) | 72 (9.9%) | 0.91 | 0.67–1.25 | 0.565 | |
| Self-employed | 526 (15.0%) | 413 (14.9%) | 113 (15.6) | 0.97 | 0.75–1.26 | 0.840 | |
| Student | 146 (4.2%) | 93 (3.4%) | 53 (7.3%) | 0.83 | 0.56–1.24 | 0.360 | |
| Housewife | 94 (2.7%) | 88 (3.2%) | 6 (0.8%) | 1.18 | 0.47–2.94 | 0.723 | |
| Other | 278 (7.9%) | 244 (8.8%) | 34 (4.7%) | 0.69 | 0.46–1.05 | 0.083 | |
| Unknown | 518 (14.8%) | 398 (14.3%) | 120 (16.5%) | 0.99 | 0.75–1.30 | 0.929 | |
|
| |||||||
| <1000 | 122 (3.5%) | 99 (3.6%) | 23 (3.2%) | 0.005 | 0.66 | 0.39–1.12 | 0.127 |
| 1000–10,000 | 559 (16.0%) | 445 (16.1%) | 114 (15.7%) | 0.81 | 0.61–1.08 | 0.147 | |
| 10,000–100,000 | 1470 (42.0%) | 1126 (40.6%) | 344 (47.4%) | 0.94 | 0.75–1.17 | 0.562 | |
| >100,000 | 1118 (32.0%) | 905 (32.6%) | 213 (29.3%) | 1.00 | - | ||
| Unknown | 230 (6.6%) | 198 (7.1%) | 32 (4.4%) | 0.76 | 0.38–1.55 | 0.451 | |
|
| |||||||
| ≤200 | 791 (22.6%) | 721 (26.0%) | 70 (9.6%) | <0.001 | 1.00 | - | - |
| 201–500 | 1485 (42.4%) | 1165 (42.0%) | 320 (44.1%) | 2.22 | 1.64–2.99 | <0.001 | |
| >500 | 1003 (28.7%) | 703 (25.4%) | 300 (41.3%) | 3.01 | 2.20–4.13 | <0.001 | |
| Unknown | 220 (6.3%) | 184 (6.6%) | 36 (5.0%) | 1.90 | 0.93–3.90 | 0.078 | |
|
| 2011 | 2011 | 2012 | <0.001 | 1.09 | 1.06–1.11 | <0.001 |
|
| |||||||
| A1 | 104 (3.0%) | 85 (3.1%) | 19 (2.6%) | <0.001 | - | - | - |
| B | 2556 (73.1%) | 2038 (73.5%) | 518 (71.4%) | - | - | - | |
| C | 148 (4.2%) | 119 (4.3%) | 29 (4.0%) | - | - | - | |
| CRF02_AG | 187 (5.3%) | 141 (5.1%) | 46 (6.3%) | - | - | - | |
| CRF60_BC | 64 (1.8%) | 12 (0.4%) | 52 (7.2%) | - | - | - | |
| F1 | 179 (5.1%) | 157 (5.7%) | 22 (3.0%) | - | - | - | |
| Other | 261 (7.5%) | 221 (8.0%) | 40(5.5%) | - | - | - | |
|
| |||||||
| Any drug class | 501 (14.3) | 420 (15.1) | 81 (11.2) | 0.006 | - | - | - |
| NNRTI | 335 (9.6) | 281 (10.1) | 54 (7.4) | 0.028 | - | - | - |
| NRTI | 150 (4.3) | 134 (4.8) | 16 (2.2) | 0.002 | - | - | - |
| PI | 66 (1.9) | 53 (1.9) | 13 (1.8) | 0.832 | - | - | - |
a By Mann–Whitney test (for quantitative variables) and χ2 test or Fisher’s exact test (for categorical variables), as appropriate. p-values <0.05 were considered statistically significant and were reported in bold. b Adjusted for: Sex, age, mode of HIV transmission, nation of birth, education, employment, plasma HIV-RNA, CD4 cell count, year of diagnosis. Variables that were significant in univariable analysis (p < 0.05) were considered for the multivariable model. F: female; IVDU: intravenous drug user; M: male; MSM: men who have sex with men; NNRTI: non-nucleoside reverse transcriptase inhibitor; NRTI: nucleos(t)ide reverse transcriptase inhibitor; PI: protease inhibitor.
Figure 1Clusters’ population by HIV-TRACE. The coloured geometric shapes identify the nationality and risk factors of the 3499 individuals involved in the study. Shapes without connections represent individuals not involved in molecular transmission clusters. Shapes connected with lines represent individuals involved in molecular transmission clusters.
Characteristics of molecular transmission clusters found among 3499 drug-naïve individuals living in Italy.
| Cluster’s Characteristics | Small Clusters | Medium Clusters | Large Clusters | ||
|---|---|---|---|---|---|
| Overall | Clusters of 2 Persons | Clusters of 3 Persons | |||
|
| 2–3 | - | - | 4–9 | 10–52 |
|
| 19–65 | 19–65 | 20–56 | 18–53 | 18–58 |
|
| |||||
| Only MSM | 101 (54.3%) | 82 (52.5%) | 19 (63.3%) | 18 (50.0%) | - |
| Only heterosexual (F+M) | 13 (7.0%) | 13 (8.3%) | - | - | - |
| Only heterosexual (only F) | 4 (2.2%) | 4 (2.6%) | - | - | - |
| Only heterosexual (only M) | 5 (2.7%) | 5 (3.2%) | - | - | - |
| Only IVDU (F+M) | 1 (0.5%) | 1 (0.6%) | - | - | - |
| Only IVDU (only M) | 2 (1.1%) | 2 (1.3%) | - | - | - |
| Mixed (F+M) | 18 (9.7%) | 9 (5.8%) | 4 (13.3%) | 4 (11.1%) | 1 (16.7%) |
| Mixed (only M) | 42 (22.5%) | 40 (25.5%) | 7 (23.3%) | 14 (38.9%) | 5 (83.3%) |
|
| |||||
| Only Italians | 137 73.7%) | 122 (78.2%) | 15 (50.0%) | 24 (66.7%) | 2 (33.3%) |
| Italians and migrants | 43 (23.1%) | 28 (18.0%) | 15 (50.0%) | 12 (33.3%) | 4 (66.7%) |
| Only migrants | 6 (3.2%) | 6 (3.8%) | - | - | - |
|
| |||||
| A1 | 3 (1.6%) | 2 (1.2%) | 1 (3.3%) | 2 (5.6%) | - |
| B | 149 (80.1%) | 125 (80.1%) | 24 (80.0%) | 25 (69.3%) | 3 (50.0%) |
| C | 5 (2.7%) | 4 (2.6%) | 1 (3.3%) | 2 (5.6%) | 1 (16.7%) |
| CRF02_AG | 5 (2.7%) | 3 (1.9%) | 2 (6.7%) | 5 (13.9%) | 1 (16.7%) |
| CRF60_BC | - | - | - | - | 1 (16.7%) |
| F1 | 11 (5.9%) | 11 (7.1%) | - | - | - |
| Other | 13 (7.0%) | 11 (7.1%) | 2 (6.7%) | 2 (5.6%) | - |
|
| |||||
| None | 150 (80.7) | 123 (78.8) | 27 (90.0) | 31 (86.1) | 5 (83.3) |
| Any drug class | 36 (19.3) | 33 (21.2) | 3 (10.0) | 5 (13.9) | 1 (16.7) |
| NNRTI | 24 (12.9) | 22 (14.1) | 2 (6.7) | 3 (8.3) | 1 (16.7) |
| NRTI | 6 (3.2) | 5 (3.2) | 1 (3.3) | 1 (2.8) | 0 (0.0) |
| PI | 7 (3.8) | 7 (4.5) | 0 (0.0) | 1 (2.8) | 0 (0.0) |
IVDU: intravenous drug user; MSM: men who have sex with men; NNRTI: non-nucleoside reverse transcriptase inhibitor; NRTI: nucleos(t)ide reverse transcriptase inhibitor; PI: protease inhibitor.
Clusters characteristics.
| Medium MTCs (4–9 Sequences) | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| ID | Subtype | Cluster Size a | Sampling Interval Year | HIV Diagnosis Interval Year | Migrants | Migrants’ Nationality | Age, Years | Risk Factor | Genetic Distance | Resistance |
| 1 | B | 4 | 2006–2007 | 2006–2007 | 0 (0.0) | - | 46 (44–46) | 4 MSM | 0.008 (0.002) | No |
| 2 | B | 4 | 2007–2012 | 2004–2012 | 0 (0.0) | - | 46 (42–50) | 1 F Het, 2 M Het, 1 M Unk | 0.010 (0.002) | No |
| 3 | B | 4 | 2008–2014 | 2008–2014 | 0 (0.0) | - | 52 (50–53) | 4 MSM | 0.008 (0.002) | No |
| 4 | B | 4 | 2008–2016 | 2008–2016 | 0 (0.0) | - | 39 (37–41) | 3 MSM, 1 M Unk | 0.006 (0.002) | No |
| 5 | B | 4 | 2009–2012 | 2009–2012 | 0 (0.0) | - | 54 (51–56) | 3 MSM, 1 F Het | 0.009 (0.002) | No |
| 6 | B | 4 | 2009–2016 | 2009–2016 | 0 (0.0) | - | 36 (33–41) | 3 MSM, 1 M Unk | 0.009 (0.002) | Yes ( |
| 7 | B | 4 | 2010–2011 | 2010 | 1 (25.0) | 1 NA | 50 (46–52) | 4 MSM | 0.004 (0.002) | No |
| 8 | B | 4 | 2011–2013 | 2011–2013 | 0 (0.0) | - | 37 (35–38) | 4 MSM | 0.008 (0.002) | No |
| 9 | B | 4 | 2011–2017 | 2011–2017 | 0 (0.0) | - | 53 (48–56) | 4 MSM | 0.007 (0.002) | No |
| 10 | B | 4 | 2013–2014 | 2010–2014 | 0 (0.0) | - | 41 (34–48) | 4 MSM | 0.006 (0.002) | No |
| 11 | B | 4 | 2013–2018 | 2013–2018 | 1 (25.0) | 1 EE | 41 (37–43) | 3 MSM, 1 M Het | 0.008 (0.002) | No |
| 12 | B | 4 | 2016 | 2015–2016 | 0 (0.0) | - | 38 (28–49) | 4 MSM | 0.004 (0.001) | Yes ( |
| 13 | B | 5 | 2007–2012 | 2007–2011 | 1 (20.0) | 1 NA | 38 (37–45) | 5 MSM | 0.006 (0.001) | No |
| 14 | B | 5 | 2008–2014 | 2008–2014 | 0 (0.0) | - | 36 (36–37) | 5 MSM | 0.011 (0.002) | No |
| 15 | B | 5 | 2010–2012 | 2009–2012 | 2 (40.0) | 1 CA, 1 EE | 41 (37–43) | 5 MSM | 0.008 (0.002) | No |
| 16 | B | 5 | 2011–2017 | 2008–2017 | 0 (0.0) | - | 38 (37–45) | 4 MSM, 1 M Het | 0.009 (0.002) | No |
| 17 | B | 5 | 2011–2017 | 2011–2017 | 0 (0.0) | - | 33 (32–35) | 5 MSM | 0.009 (0.002) | Yes ( |
| 18 | B | 5 | 2013–2018 | 2013–2018 | 1 (20.0) | 1 SA | 38 (36–43) | 3 MSM, 2 M Het | 0.011 (0.002) | No |
| 19 | B | 6 | 2007–2011 | 2006–2011 | 0 (0.0) | - | 41 (36–48) | 6 MSM | 0.010 (0.002) | No |
| 20 | B | 6 | 2007–2011 | 2007–2011 | 0 (0.0) | - | 42 (37–45) | 5 MSM, 1 M Unk | 0.011 (0.002) | No |
| 21 | B | 6 | 2010–2014 | 2010–2014 | 0 (0.0) | - | 37 (35–43) | 5 MSM, 1 M Het | 0.011 (0.002) | No |
| 22 | B | 7 | 2006–2016 | 2006–2009 | 1 (14.3) | 1 SA | 43 (39–48) | 7 MSM | 0.010 (0.002) | No |
| 23 | B | 7 | 2009–2014 | 2008–2014 | 2 (28.6) | 2 SA | 51 (40–53) | 7 MSM | 0.011 (0.002) | No |
| 24 | B | 9 | 2010–2016 | 2010–2014 | 0 (0.0) | - | 40 (34–52) | 7 MSM, 1 M Het, 1 M Unk | 0.009 (0.002) | No |
| 25 | B | 9 | 2017–2018 | 2017–2018 | 0 (0.0) | - | 34 (31–41) | 8 MSM, 1 M Unk | 0.006 (0.001) | No |
| 26 | A1 | 4 | 2013–2015 | 2013–2015 | 0 (0.0) | - | 47 (45–50) | 4 MSM | 0.010 (0.002) | No |
| 27 | A1 | 8 | 2014–2016 | 2013–2016 | 1 (12.5) | 1 WE | 37 (33–39) | 8 MSM | 0.008 (0.002) | No |
| 28 | C | 4 | 2007–2011 | 2006–2011 | 1 (25.0) | 1 SA | 46 (44–47) | 3 MSM, 1 M Het | 0.007 (0.002) | No |
| 29 | C | 4 | 2012–2016 | 2012–2016 | 0 (0.0) | - | 50 (45–52) | 3 M Het, 1 M MSM | 0.009 (0.002) | No |
| 30 | CRF02_AG | 4 | 2009–2013 | 2009–2012 | 0 (0.0) | - | 35 (35–37) | 4 MSM | 0.007 (0.002) | No |
| 31 | CRF02_AG | 4 | 2009–2013 | 2009–2013 | 0 (0.0) | - | 38 (38–40) | 2 MSM, 1 F Het, 1 M Unk | 0.004 (0.001) | No |
| 32 | CRF02_AG | 4 | 2014 | 2014 | 1 (25.0) | 1 EE | 34 (30–39) | 3 MSM, 1 M Het | 0.009 (0.002) | Yes ( |
| 33 | CRF02_AG | 5 | 2013–2014 | 2012–2014 | 0 (0.0) | - | 34 (33–35) | 4 MSM, 1 M Unk | 0.006 (0.002) | No |
| 34 | CRF02_AG | 7 | 2010–2017 | 2010–2016 | 0 (0.0) | - | 41 (36–51) | 6 MSM, 1 M Het | 0.005 (0.001) | No |
| 35 | CRF12_BF | 5 | 2014–2015 | 2013–2015 | 1 (20.0) | 1 SA | 34 (27–34) | 2 F Het; 2 M Het, 1 M Unk | 0.010 (0.002) | Yes ( |
| 36 | CRF20_BG | 7 | 2013–2017 | 2013–2017 | 1 (14.3) | 1 Aus | 33 (32–37) | 7 MSM | 0.005 (0.001) | No |
|
| ||||||||||
| 1 | B | 14 | 2008–2016 | 2008–2016 | 0 (0.0) | - | 40 (34–49) | 11 MSM, 2 M Het, 1 M IVDU | 0.010 (0.001) | No |
| 2 | B | 19 | 2007–2015 | 2007–2015 | 2 (10.5) | 1 EE, 1 SA | 37 (32–43) | 18 MSM, 1 M Unk | 0.016 (0.002) | No |
| 3 | B | 35 | 2009–2017 | 2009–2017 | 2 (5.7) | 1 WE, 1 SA | 34 (33–43) | 33 MSM, 1 M Het, 1 M Unk | 0.013 (0.002) | No |
| 4 | C | 10 | 2011–2016 | 2011–2016 | 0 (0.0) | - | 39 (35–42) | 8 MSM, 1 M Het, 1 M Unk | 0.009 (0.001) | No |
| 5 | CRF02_AG | 10 | 2006–2016 | 2006–2016 | 1 (10.0) | 1 CA | 42 (35–46) | 9 MSM, 1 M Het | 0.011 (0.002) | No |
| 6 | CRF60_BC | 52 | 2008–2018 | 2008–2018 | 5 (9.6) | 4 EE, 1 Unk | 34 (31–37) | 41 MSM, 2 F Het, 3 M Het, 6 M Unk | 0.012 (0.001) | Yes ( |
a Number of individuals involved in a specific MTC. Het: heterosexual; MSM: men who have sex with men; Unk: unknown; PR: protease; RT: reverse transcriptase. Aus: Australian, CA: Central American; EE: East European; F: female; M: male; NA: North American; SA: South American; WE: West European.